A Phase III, multi-center, randomized, double-blind, 48 week study with an initial 12 week placebo-controlled period to evaluate the safety and efficacy of osilodrostat in patients with Cushings disease.
Sponsor: |
Novartis |
Enrolling: |
Male and Female Patients |
IRB Number: |
AAAQ8154 |
U.S. Govt. ID: |
NCT02697734 |
Contact: |
Pamela Freda: 212-305-2254 / puf1@cumc.columbia.edu |
This study is for individuals who have Cushings disease and want to join voluntarily in this study to find out if a study drug called osilodrostat (LCI699) is safe and has beneficial effects in people who have Cushings disease. Cushings disease is a rare but debilitating disease. Cushings disease is caused by a benign tumor of the pituitary gland. The tumor causes the adrenal glands to secrete too much of a hormone called cortisol. Most of the harmful effects in Cushings disease are the result of too much cortisol. The purpose of this study is to confirm the effectiveness and safety of osilodrostat in treating patients with this medical condition.
This study is closed
Investigator
Pamela Freda, MD
Have you been diagnosed with Cushing's Disease? |
Yes |
No |